1
|
Pui CH: Childhood Leukemias. 3rd.
Cambridge University Press; Cambridge: 2012, View Article : Google Scholar
|
2
|
Pui CH and Jeha S: New therapeutic
strategies for the treatment of acute lymphoblastic leukaemia. Nat
Rev Drug Discov. 6:149–165. 2007. View
Article : Google Scholar : PubMed/NCBI
|
3
|
Libermann TA and Zerbini LF: Targeting
transcription factors for cancer gene therapy. Curr Gene Ther.
6:17–33. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Brown M, Cohen J, Arun P, Chen Z and Van
Waes C: NF-kappaB in carcinoma therapy and prevention. Expert Opin
Ther Targets. 12:1109–1122. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Montagut C, Tusquets I, Ferrer B,
Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo
E, Gascon P, et al: Activation of nuclear factor-kappaB is linked
to resistance to neoadjuvant chemotherapy in breast cancer
patients. Endocr Relat Cancer. 13:607–616. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
7
|
Kordes U, Krappmann D, Heissmeyer V,
Ludwig WD and Scheidereit C: Transcription factor NF-kappaB is
constitutively activated in acute lymphoblastic leukemia cells.
Leukemia. 14:399–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sethi G, Sung B and Aggarwal BB: Nuclear
factor-kappaB activation: From bench to bedside. Exp Biol Med
(Maywood). 233:21–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ravindran J, Prasad S and Aggarwal BB:
Curcumin and cancer cells: How many ways can curry kill tumor cells
selectively? AAPS J. 11:495–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Lao CD, Ruffin MT IV, Normolle D, Heath
DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL and Brenner
DE: Dose escalation of a curcuminoid formulation. BMC Complement
Altern Med. 6:102006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Gupta SC, Kismali G and Aggarwal BB:
Curcumin, a component of turmeric: From farm to pharmacy.
Biofactors. 39:2–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Beillard E, Pallisgaard N, van der Velden
VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E,
Gottardi E, Saglio G, et al: Evaluation of candidate control genes
for diagnosis and residual disease detection in leukemic patients
using 'real-time' quantitative reverse-transcriptase polymerase
chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia. 17:2474–2486. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Anand P, Sundaram C, Jhurani S,
Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: An ‘old-age’
disease with an ‘age-old’ solution. Cancer Lett. 267:133–164. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen Y, Jungsuwadee P, Vore M, Butterfield
DA and St Clair DK: Collateral damage in cancer chemotherapy:
Oxidative stress in nontargeted tissues. Mol Interv. 7:147–156.
2007. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Blakemore LM, Boes C, Cordell R and Manson
MM: Curcumin-induced mitotic arrest is characterized by spindle
abnormalities, defects in chromosomal congression and DNA damage.
Carcinogenesis. 34:351–360. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Xue TY, Xu W, An Q, Wu Y, Xu CP and Zhang
XY: Expression of nuclear transcription factor kappaB in childhood
acute lymphoblastic leukemia and its significance. Zhongguo Shi Yan
Xue Ye Xue Za Zhi. 15:767–771. 2007.(In Chinese). PubMed/NCBI
|
18
|
Bottero V, Busuttil V, Loubat A, Magné N,
Fischel JL, Milano G and Peyron JF: Activation of nuclear factor
kappaB through the IKK complex by the topoisomerase poisons SN38
and doxorubicin: A brake to apoptosis in HeLa human carcinoma
cells. Cancer Res. 61:7785–7791. 2001.PubMed/NCBI
|
19
|
Aggarwal BB and Gehlot P: Inflammation and
cancer: How friendly is the relationship for cancer patients? Curr
Opin Pharmacol. 9:351–369. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Karin M: NF-kappaB as a critical link
between inflammation and cancer. Cold Spring Harb Perspect Biol.
1:a0001412009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Anto RJ, Mukhopadhyay A, Denning K and
Aggarwal BB: Curcumin (diferuloylmethane) induces apoptosis through
activation of caspase-8, BID cleavage and cytochrome c release: Its
suppression by ectopic expression of Bcl-2 and Bcl-xl.
Carcinogenesis. 23:143–150. 2002. View Article : Google Scholar : PubMed/NCBI
|
23
|
Shishodia S, Amin HM, Lai R and Aggarwal
BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB
activation, induces G1/S arrest, suppresses proliferation, and
induces apoptosis in mantle cell lymphoma. Biochem Pharmacol.
70:700–713. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kasinski AL, Du Y, Thomas SL, Zhao J, Sun
SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP, et al: Inhibition
of IkappaB kinase-nuclear factor-kappaB signaling pathway by
3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel
monoketone analog of curcumin. Mol Pharmacol. 74:654–661. 2008.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Wang H, Geng QR, Wang L and Lu Y: Curcumin
potentiates antitumor activity of L-asparaginase via inhibition of
the AKT signaling pathway in acute lymphoblastic leukemia. Leuk
Lymphoma. 57:1376–1382. 2012. View Article : Google Scholar
|
26
|
Somasundaram S, Edmund NA, Moore DT, Small
GW, Shi YY and Orlowski RZ: Dietary curcumin inhibits
chemotherapy-induced apoptosis in models of human breast cancer.
Cancer Res. 62:3868–3875. 2002.PubMed/NCBI
|
27
|
Bharti AC, Donato N, Singh S and Aggarwal
BB: Curcumin (diferuloylmethane) down-regulates the constitutive
activation of nuclear factor-kappa B and IkappaBalpha kinase in
human multiple myeloma cells, leading to suppression of
proliferation and induction of apoptosis. Blood. 101:1053–1062.
2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chan WH, Wu HY and Chang WH: Dosage
effects of curcumin on cell death types in a human osteoblast cell
line. Food Chem Toxicol. 44:1362–1371. 2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Al-Katib A, Arnold AA, Aboukameel A, Sosin
A, Smith P, Mohamed AN, Beck FW and Mohammad RM: I-kappa-kinase-2
(IKK-2) inhibition potentiates vincristine cytotoxicity in
non-Hodgkin's lymphoma. Mol Cancer. 9:2282010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wang H, Geng QR, Wang L and Lu Y: Curcumin
potentiates antitumor activity of L-asparaginase via inhibition of
the AKT signaling pathway in acute lymphoblastic leukemia. Leuk
Lymphoma. 53:1376–1382. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
32
|
Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS,
Wu X, Zhou WH, Huang RW and Liu Q: Curcumin reduces expression of
Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute
myeloid leukemia cell lines and primary sorted CD34+ acute myeloid
leukemia cells. J Transl Med. 9:712011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Chen Y, Jungsuwadee P, Vore M, Butterfield
DA and St Clair DK: Collateral damage in cancer chemotherapy:
Oxidative stress in nontargeted tissues. Mol Interv. 7:147–156.
2007. View
Article : Google Scholar : PubMed/NCBI
|
34
|
Valavanidis A, Vlachogianni T and Fiotakis
C: 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of
oxidative stress and carcinogenesis. J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev. 27:120–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
35
|
Thangapazham RL, Sharma A and Maheshwari
RK: Multiple molecular targets in cancer chemoprevention by
curcumin. AAPS J. 8:E443–E449. 2006. View Article : Google Scholar : PubMed/NCBI
|
36
|
Mahakunakorn P, Tohda M, Murakami Y,
Matsumoto K, Watanabe H and Vajaragupta O: Cytoprotective and
cytotoxic effects of curcumin: Dual action on H2O2-induced
oxidative cell damage in NG108-15 cells. Biol Pharm Bull.
26:725–728. 2003. View Article : Google Scholar : PubMed/NCBI
|
37
|
Dhillion N, Aggarwal BB, Newman RA, Wolff
RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock
R: Phase II trial of curcumin in patients with advanced pancreatic
cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI
|
38
|
He ZY, Shi CH, Wen H, Li FL, Wang BL and
Wang J: Upregulation of p53 expression in patients with colorectal
cancer by administration of curcumin. Cancer Invest. 29:208–213.
2011. View Article : Google Scholar : PubMed/NCBI
|
39
|
Anuchapreeda S, Thanarattanakorn P,
Sittipreechacharn S, Tima S, Chanarat P and Limtrakul P: Inhibitory
effect of curcumin on MDR1 gene expression in patient leukemic
cells. Arch Pharm Res. 29:866–873. 2006. View Article : Google Scholar : PubMed/NCBI
|